Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE-CAP: Capivasertib Safety in HR+/HER2- Metastatic Breast Cancer
NCT07426822Phase 2Recruiting
- Sponsor
- Maryam Lustberg
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capivasertib in breast cancer, sponsored by Maryam Lustberg. Started Aug 2026; status: recruiting.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07426822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07426822.